Back to News
Jun 15, 2026 4:00 PM

Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

The six-month data shared on Saturday showed improvements in body mass index, body composition, hyperphagia, and behavioral measures.

The company presented the findings at the Endocrine Society’s Annual Meeting, ENDO 2026.

Read Also:

Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy

The trial enrolled 18 patients between the ages of 6 and 23 who met obesity-related eligibility criteria. As of June 12, 2026, 17 participants remained on active treatment in the 52-week study.

BMI And Body Composition Trends Show Improvement

According to the six-month analysis, patients receiving setmelanotide recorded a